http://www.mmm-online.com/pipeline/topic/213/ Articles tagged with Pipeline from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug. http://www.mmm-online.com/jj-expands-pipeline-in-prostate-cancer/article/299070/ Mon, 17 Jun 2013 16:55:44 GMT The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug. MMM Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data. http://www.mmm-online.com/novartis-readying-2014-filing-for-lung-cancer-drug/article/296328/ Tue, 04 Jun 2013 18:09:16 GMT Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data. MMM GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines. http://www.mmm-online.com/gsk-gets-2-cancer-pills-approved-but-a-deeper-question-is-left-unanswered/article/295559/ Thu, 30 May 2013 18:55:57 GMT GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines. MMM Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement. http://www.mmm-online.com/business-briefs-merck-and-forest-labs/article/294660/ Thu, 23 May 2013 18:27:46 GMT Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement. MMM J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon. http://www.mmm-online.com/jjs-janssen-looks-to-the-margins-with-hep-c-agent/article/293322/ Tue, 14 May 2013 17:10:47 GMT J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon. MMM Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective. http://www.mmm-online.com/data-show-gileads-sofosbuvir-has-clean-safety-profile/article/290298/ Wed, 24 Apr 2013 14:56:10 GMT Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective. MMM FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs. http://www.mmm-online.com/pfizer-pipeline-breast-cancer-drug-gets-fast-tracked/article/288456/ Thu, 11 Apr 2013 17:05:52 GMT FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs. MMM Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive. http://www.mmm-online.com/oncology-lifts-roches-q1-lucentis-finds-new-fans/article/288379/ Thu, 11 Apr 2013 15:20:25 GMT Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive. MMM Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016. http://www.mmm-online.com/more-pink-slips-at-astrazeneca/article/285381/ Thu, 21 Mar 2013 15:13:01 GMT Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016. MMM HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices. http://www.mmm-online.com/business-briefs-gilead-shire-the-medicines-co-hhs/article/278976/ Mon, 04 Feb 2013 19:21:27 GMT HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices. MMM